Andrew Beale is most often covered alongside Arete Research, which appears in 2 of these 2 stories. The 13-day window averages about 1.1 stories each week. Each story carries 3 original sources on average, compared with 4.8 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Andrew Beale
Andrew Beale is most often covered alongside Arete Research, which appears in 2 of these 2 stories. The 13-day window averages about 1.1 stories each week. Each story carries 3 original sources on average, compared with 4.8 for the broader beat in this window. The clearest coverage concentration is aerospace: 1 of 2 stories, with the rest divided among 1 other category. The 7 average consequence score is below the beat benchmark of 7.2 in the same window. We currently track 2 Space & Defense stories that mention Andrew Beale, published between June 21, 2026 and July 3, 2026.
Stories tracked
2
Per week
1.1
Sources per story
3
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 75 Space & Defense stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Andrew Beale. Shared-story counts are live from our verified record — not editorial picks.
With the IPO quiet period expiring on July 7, SpaceX will finally get analyst ratings just as Starship and StarlinkV3 move toward deployment. The most bullish call sees $401. For aerospace investors, the impending coverage wave will clarify whether the market is properly valuing the company’s next-generation space and satellite assets.
Arete Research’s $401 price target for SpaceX isn’t just a financial call—it’s a wager on Starship achieving commercial viability. Without that heavy-lift rocket, the Starlink V3 satellites that form the analyst’s thesis remain grounded, leaving the stock’s upside highly uncertain.